OrthoPediatrics Corp.

OrthoPediatrics Corp.

KIDSNYSE / NASDAQHealthcareSmall cap

$31.74-$0.77 (-2.4%)

Last close · Data as of Nov 20, 2026

Market cap
$464.9M
P/E
-11.7x
EV / EBITDA
-69.2x
Revenue
$236.3M
Net margin
-16.8%
ROCE
-6.3%

+88.1% over the last year

OrthoPediatrics Corp. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+35.1%
3M
+21.0%
6M
+71.6%
1Y
+88.1%
5Y
-48.2%

52-week range

Day change -$0.77 (-2.4%) from $33 to $32 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in KIDS, bought on each weekday since 2021.

News & filings

What OrthoPediatrics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 39.6 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 53.7% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally.

Read moreShow less

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Sector
Healthcare
Shares outstanding
25.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$464.9M
P/E
-11.7x
P/B
1.3x
EV / EBITDA
-69.2x
EV / Sales
2.3x
P/S
2.0x
52-week high
$33.99
52-week low
$14.64

Profitability

Operating margin
-12.3%
Net margin
-16.8%
EBITDA margin
-3.3%
ROE
-11.4%
ROCE
-6.3%
ROIC
-5.4%
ROA
-7.8%
Asset turnover
0.46

Growth

Revenue
$236.3M
Revenue growth, 1Y
15.4%
Revenue CAGR, 3Y
24.6%
Net profit growth, 1Y
4.8%
Free cash flow
-$16.0M

Solvency

Current ratio
5.55
Debt / Equity
0.29
Debt / Assets
0.20
CFO / Net profit
0.12
Cash / Market cap
4.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$236.3M
Cost of revenue$63.7M
Gross profit$172.7M
Operating expenses$201.7M
Research and development$9.1M
Selling, general and administrative$192.6M
Operating income-$29.0M
Interest and other-$10.2M
Pretax income-$39.2M
Tax and other$460.0k
Net income-$39.6M

Revenue and net profit

Revenue grew 15.4% in FY2025; net profit is the dashed line.

OrthoPediatrics Corp. revenue and net profit by fiscal year
OrthoPediatrics Corp. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$122.3M$1.3M
FY2023$148.7M-$21.0M
FY2024$204.7M-$37.8M
FY2025$236.3M-$39.6M

Cash flows

FY2025: -$4.9M from operations, -$16.0M free after investment (dashed).

OrthoPediatrics Corp. operating and free cash flow by fiscal year
OrthoPediatrics Corp. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$21.8M-$31.8M
FY2023-$27.0M-$43.9M
FY2024-$27.0M-$41.3M
FY2025-$4.9M-$16.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$236.3M+15.4%1Y
EBITDA
-$7.9M
Net profit
-$39.6M
Cash from operations
-$4.9M
Free cash flow
-$16.0M
Revenue CAGR, 3Y
24.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$236.3M-$7.9M-$39.6M-$16.0M-11.4%+15.4%+4.8%

Monthly returns

Month-by-month returns of KIDS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$508.6M
Liabilities$162.0M
Equity$346.6M
Paid-in capital$622.3M
Retained earnings-$275.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; KIDS highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. CTEV5.3x
  2. OrthoPediatrics Corp. (this company)2.3x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
OrthoPediatrics Corp.KIDSthis company$464.9M-11.7x1.3x-11.4%-69.2x
Prothena Corporation plcPRTA$484.3M-2.0x1.7x-87.0%-1.0x
The Oncology Institute, Inc.TOI$473.9M-7.8x-30.1x385.5%-12.8x
CTEVCTEV$470.0M——163.5%10.8x
Weave Communications, Inc.WEAV$459.1M-16.4x5.6x-34.1%-42.3x
Editas Medicine, Inc.EDIT$458.9M-2.9x16.8x-586.6%-2.2x
NRC HealthNRC$445.1M38.4x31.8x82.9%17.2x
Myriad Genetics, Inc.MYGN$443.0M-1.2x1.2x-99.4%-1.5x
Varex Imaging CorporationVREX$440.9M—0.9x-14.9%973.8x
Peer median—-2.4x1.7x-24.5%-1.3x

Year-to-date ROI

KIDS since 1 January, against earlier years.

Historical volatility

KIDS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

OrthoPediatrics Corp. operating margin by fiscal year
OrthoPediatrics Corp. operating margin by fiscal year
DateOperating margin
FY2022-17.8%
FY2023-17.3%
FY2024-14.4%
FY2025-12.3%
LineFY2025
Cost of revenueCost Of Revenue$63.7M
Gross profitGross Profit$172.7M
Operating expensesOperating Expense$201.7M
Research and developmentResearch And Development$9.1M
Total expensesTotal Expenses$265.4M
Pretax incomePretax Income-$39.2M

Learn while you research

Academy chapters picked for OrthoPediatrics Corp. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →